The FDA has approved Phesgo™ (pertuzumab, trastuzumab, hyaluronidase-zzxf; Genentech), in combination with chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.
Polygenic risk scores incorporating scores of SNPs associated with breast cancer risk have been used as breast cancer risk-stratification tools.
Race and ethnicity were key data points collected from the cohort and tracked with outcomes.
The detection of acquired ESR1 mutations in patients with hormone receptor (HR) positive metastatic breast cancer predicted poor clinical benefit from exemestane.
The incidence of breast cancer for postmenopausal women included in the NIH-AARP study was evaluated with respect to level of outdoor light at night.
The TC model uses various parameters to predict risk such as genetic risk and nonfamilial factors including personal, hormonal, and lifestyle characteristics.
Patients with early-stage breast cancer who undergo mastectomy with or without reconstruction are at risk of prolonged opioid use.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Larger surgical margin widths were associated with a lower rate of invasive breast cancer in certain individuals.
Controversy exists regarding whether to offer early locoregional treatment in addition to palliative therapy to patients with de novo MBC and an intact primary tumor.
